Accueil・Liste d'Actions・Neurocrine Biosciences Inc

Neurocrine Biosciences Inc

Ouvert

SecteurSoins de santé

152.22 1.28

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

148.4

Max

153.31

Chiffres clés
By Trading Economics
Revenu	-54M 144M
Ventes	145M 959M
P/E Moyenne du Secteur	23.867 57.002
BPA	2.36
Marge bénéficiaire	15.057
Employés	2,500
EBITDA	-64M 190M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+39.5% upside

Dividendes
By Acuity
Prochains Résultats	27 oct. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-974M 17B
Ouverture précédente	150.94
Clôture précédente	152.22

Sentiment de l'Actualité

By Acuity

50%

171 / 340 Classement par Healthcare

Neurocrine Biosciences Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 août 2026, 20:02 UTC

News

Event

Neurocrine Biosciences shares decline as Morgan Stanley lowers price target to $182, citing safety concerns over VYKAT XR and reports of serious adverse events.

12 août 2026, 21:11 UTC

Event

Neurocrine Biosciences published positive KINECT-PRO™ study results, yet shares are lower in after-market hours, continuing a trend of declining daily closes.

10 août 2026, 19:36 UTC

Event

Neurocrine Biosciences initiates a Phase 1 study for NBIP-'1968, contributing to a rise in shares during the session. The stock remains below its 20-day moving average.

7 août 2026, 19:46 UTC

News

Event

Social Media

Neurocrine Biosciences initiates a Phase 1 study for NBIP-'1968, a GLP-1/GIP/glucagon receptor triple agonist for obesity, boosting shares during Friday's session.

6 août 2026, 19:36 UTC

Neurocrine Biosciences Inc shares are lower during Thursday's session, continuing a decline since Wednesday's close, with no specific news identified.

5 août 2026, 23:46 UTC

Neurocrine Biosciences Inc shares are higher in after-market trading, buoyed by investor interest despite disappointing private sector employment data.

4 août 2026, 19:26 UTC

News

Wedbush raised its price target on Neurocrine Biosciences to $194, while Canaccord Genuity increased its target to $210. Shares are trading roughly flat.

3 août 2026, 20:51 UTC

Neurocrine Biosciences Inc shares are higher in after-market trading, reflecting a positive trend in the biotechnology sector amid broader market gains.

31 juil. 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

30 juil. 2026, 21:51 UTC

News

Neurocrine Biosciences reported second-quarter revenues of $959 million and raised 2026 INGREZZA sales guidance, with shares trading higher in after-market hours.

29 juil. 2026, 18:46 UTC

Neurocrine Biosciences Inc shares are trading lower today with no specific news identified. The stock fluctuated earlier in the session amid broader market activity.

28 juil. 2026, 23:41 UTC

Neurocrine Biosciences Inc shares are higher in after-market hours, rebounding from an earlier dip and maintaining a position above the 20-day moving average.

27 juil. 2026, 19:21 UTC

Social Media

Neurocrine Biosciences shares are higher as Cantor Schimmer ranks it among top picks, citing undervaluation and expected advancements in its portfolio.

24 juil. 2026, 20:07 UTC

Neurocrine Biosciences Inc shares are higher today, despite an earlier pullback. Broader market sentiment is influenced by falling oil prices easing inflation concerns.

22 juil. 2026, 19:51 UTC

News

Neurocrine Biosciences Inc. appointed Samir Siddhanti as Chief Business Officer. Despite this leadership change, shares are trading lower amid cautious investor sentiment.

21 juil. 2026, 19:51 UTC

News

Neurocrine shares rise after Guggenheim raises price target to $200.

20 juil. 2026, 23:46 UTC

Neurocrine Biosciences Inc is trading higher in after-market hours, maintaining a strong performance above its 20-day moving average and near its one-month range.

Comparaison

Variation de prix

Neurocrine Biosciences Inc prévision

Objectif de Prix

By TipRanks

39.5% hausse

Prévisions sur 12 Mois

Moyen 210.4 USD 39.5%

Haut 249 USD

Bas 165 USD

Basé sur 26 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

26 ratings

Achat

Maintien

Vente

Basé sur 26 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

171 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.